Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nanologica AB's enterprise value is kr156.22 Mil.
Nanologica AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr40.46 Mil. Therefore, Nanologica AB's EV-to-EBITDA for today is 3.86.
The historical rank and industry rank for Nanologica AB's EV-to-EBITDA or its related term are showing as below:
OSTO:NICA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.99 Med: -4.61 Max: 4.46
Current: 3.86
During the past 12 years, the highest EV-to-EBITDA of Nanologica AB was 4.46. The lowest was -34.99. And the median was -4.61.
OSTO:NICA's EV-to-EBITDA is ranked better than 71.68% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs OSTO:NICA: 3.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nanologica AB (OSTO:NICA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanologica AB's PE Ratio (TTM) for today is calculated as:
Nanologica AB's share price for today is kr0.37.
Nanologica AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.353.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nanologica AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Nanologica AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nanologica AB's EV-to-EBITDA falls into.
Nanologica AB's current Enterprise Value is kr156.22 Mil.
Nanologica AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr40.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a EV-to-EBITDA of 3.86 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nanologica AB. According to the industry distribution chart, Nanologica AB ranks #113 out of 399 companies in the Biotechnology industry, placing it in the top 28.3%.
Is Nanologica AB's EV-to-EBITDA too high?
Nanologica AB's current EV-to-EBITDA is 3.86. The Biotechnology industry median EV-to-EBITDA is 13.70. Nanologica AB's value of 3.86 is 71.8% below this industry median. Based on the distribution chart, Nanologica AB ranks #113 out of 399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #113 out of 399 companies for EV-to-EBITDA. This puts Nanologica AB in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Nanologica AB's value of 3.86 is 71.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanologica AB's current EV-to-EBITDA of 3.86 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nanologica AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current EV-to-EBITDA is 3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.92, compared to a current price of kr0.37 — trading 87.3% below its estimated fair value. The current EV-to-EBITDA is 3.86 and 71.8% below the Biotechnology industry median of 13.70. Nanologica AB's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current EV-to-EBITDA is 3.86 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.37 is trading 87.3% below its estimated GF Value™ of kr2.92.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
EV-to-EBITDA: 3.86
GF Value™: kr2.92 vs. price of kr0.37 (87.3% below fair value)
Industry Position: 71.8% below the Biotechnology median (#113 of 399)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
